McCullough Robertson’s Equity Capital Markets team has successfully advised Radiopharm Theranostics Limited (ASX: RAD; Nasdaq: RADX) on its approximately A$12.5 million institutional capital raising, comprising an Australian and international institutional placement and a concurrent US direct registered offering, together with the launch of a Share Purchase Plan (SPP) to raise up to a further A$6 million.
The capital raising received strong support from international institutional investors, including specialist healthcare funds, with commitments also secured to subscribe for up to A$3 million of any shortfall under the SPP. Proceeds will support the preparation and commencement of the Company’s RAD101 registrational Phase 3 study, the advancement of its broader therapeutic pipeline, and ongoing strategic partnering initiatives.
Having advised Radiopharm on a number of significant transactions, it was a pleasure to assist the on this successful capital raising as they continue to progress their innovative radiopharmaceutical programs and growth strategy.
